The global gene delivery technologies market size is expected to reach USD 7.86 billion by 2028 according to a new study by Polaris Market research. The report “Gene Delivery Technologies Market Share, Size, Trends, Industry Analysis Report, By Mode (Biological [Adenovirus, Retrovirus, AAV, Lentivirus, Other Viruses, Non-viral], Chemical, Physical); By Application (Gene Therapy, Cell Therapy, Vaccines, Research); By Method; By Regions; Segment Forecast, 2021 –2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
In 2020, the gene therapy market segment accounted for the largest share. Worldwide acceptance of gene therapies and subsequent rise in clinical research activities have boosted the segment’s market growth. Moreover, rising approvals for gene therapy products and services also accelerated the gene delivery technologies market growth prospects.
The vaccine market segment is projected to witness a lucrative growth rate over the gene delivery technologies study period. This is primarily due to the ability of such vaccines for different treatment approaches for both preventive and therapeutic areas. They have the potential to activate potent humoral responses. This has boosted the demand for gene editing tools for vaccine development.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/gene-delivery-technologies-market/request-for-sample
The gene delivery technologies market segment is anticipated to benefit from a sudden rise in COVID-19 cases. As of August 2020, more than 25 research groups have been working for vector-based vaccines to contain COVID-19 infection. Similarly, approximately 20 research teams are exploring approaches to develop nucleic acid vaccines.
Market participants in gene delivery technologies industry include Horizon Discovery Group Co., QIAGEN, Oxford Biomedica, SignaGen Laboratories, Hoffmann-La Roche AG, Vectalys, Sirion-Biotech GmbH, Takara Bio Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., OriGene Technologies, Inc., System Biosciences, Promega Corporation, and Catalent Inc.
The market players operating in the gene delivery technologies industry are focusing on mergers and acquisitions to stay competitive in the market. In line with this, in May 2020, Merck, completed the acquisition of Themis, an immune-modulation therapy to expand its vaccine development program for the surging COVID-19 numbers. Similarly, earlier, in May 2019, already acquired Brammer Bio, a U.S.-based company engaged in the development of viral vectors to be used in gene therapies.
Polaris Market Research has segmented the gene delivery technologies market report on the basis of mode, application, method, and region:
Gene Delivery Technologies, Mode Outlook (Revenue – USD Million, 2016 – 2028)
- Other viruses
Gene Delivery Technologies, Application Outlook (Revenue – USD Million, 2016 – 2028)
- Gene Therapy
- Cell Therapy
Gene Delivery Technologies, Method Outlook (Revenue – USD Million, 2016 – 2028)
- Ex vivo
- In vivo
- In vitro
Gene Delivery Technologies, by Regional Outlook (Revenue – USD Million, 2016 – 2028)
- North America
- Asia Pacific
- South Korea
- Central & South America
- Middle East & Africa
- Saudi Arabia
- South Africa